Zentalis gives up gains from ovarian cancer candidate data; down 11%

After closing up ~10.6% on Friday following the release of phase 1 data on ovarian cancer candidate azenosertib, Zentalis Pharmaceuticals (NASDAQ:ZNTL) has given back those gains.
As of 250p ET, the stock is down 11%.
Data released late on May 25 indicated improvements in objective response rate (ORR) and median progression free survival (mPFS), as well as signs of clinical activity.
Azenosertib, a potential first-in-class WEE1 inhibitor, was given in combination with paclitaxel or carboplatin.
When azenosertib was given with paclitaxel, the ORR was 50% and mPFS was 7.4 months. When given with carboplatin, the results were, respectively, 35.7% and 10.4 months.
Seeking Alpha's Quant Rating has viewed Zentalis (ZNTL) as a hold since May 3.